Skip to main content

Pancreatic metastases originating from uterine leiomyosarcoma: a case report

Abstract

In this report, we describe the case of a 67-year-old woman with metastatic pancreatic uterine leiomyosarcoma. She underwent a total hysterectomy and adnexectomy in December 2009. The resected uterine specimen was characterized as a leiomyosarcoma. The patient was free of disease until November 2010, when three pulmonary tumoral lesions detected by follow-up chest computed tomography were diagnosed as metastatic lesions. Wedge resections and enucleoresection of the pulmonary tumoral nodules were performed, and the patient received adjuvant chemotherapy. Ten months after the lung resection, an abdominal examination showed two tumoral masses in the pancreas and no extrapancreatic recurrence. In April 2014, a pylorus-preserving pancreaticoduodenectomy was performed. To date, the patient is alive, without any evidence of recurrence, and she has received chemotherapy. Surgery can be considered in cases in which the pancreas is a unique metastatic site or even in cases with resectable oligometastases.

Background

Uterine leiomyosarcoma (LMS) is a rare malignancy with high metastatic potential. Patients with metastatic or recurrent disease have a poor prognosis with limited treatment options. The 5-year survival rates are 53% in patients with stage I uterine LMS and 8% in those with stages II through IV disease [1, 2]. The most common sites of metastatic LMS are the lung, the peritoneal cavity and the liver [3, 4]. A case of pancreatic metastasis from a uterine LMS is rare [5, 6]. Ogura et al. identified, in a literature review, 25 cases of LMS metastases to the pancreas, of which 7 cases were from a primary uterine tumor [7]. In this report, we describe a case of a patient with metastatic pancreatic uterine LMS.

Case presentation

A 67-year-old womanwith a medical history of hypertension and hyperthyroidism presented to our hospital with postmenopausal vaginal bleeding in 2009. A transvaginal ultrasound showed a tumoral mass in the uterine wall that was initially interpreted as a leiomyoma. In December 2009, she underwent a total hysterectomy and bilateral adnexectomy. The surgically resected uterine specimen was characterized as a LMS (pT1c) with immunohistochemistry results positive for smooth muscle actin (SMA) and desmin and a Ki-67 level of 30%. No adjuvant radiochemotherapy was administered, but a follow-up examination every 6 months was recommended. The patient was free of disease until November 2010, when three pulmonary tumoral lesions 7 mm, 8.34-mm and 5 mm in size, respectively, in the inferior lobe of the left lung were detected by follow-up chest computed tomography (CT) (Figure 1). To clarify the differential diagnosis between a primary lung tumor and metastatic disease, the multidisciplinary panel decided to perform surgery.

Figure 1
figure 1

Chest computed tomography. The pulmonary nodular tumor invasion.

Wedge resections and enucleoresection of the lung tumoral nodules were performed in November 2011. The histopathological examination of the resected lung specimen revealed the presence of spindle-shaped cells with a high mitotic count. The immunohistochemistry was positive for SMA and desmin and negative for CD10, MNF116 antibody and estrogen receptor/progesterone receptor, and her Ki-67 level was 30%, thus clarifying the diagnosis of a metastatic LMS. Postoperatively, the patient received chemotherapy consisting of one cycle of Epirubicin 150 mg + Cisplatin (CDDP)100 mg and gemcitabine + vinorelbine (six cycles).

The regular follow-up CT scan obtained in July 2011, 10 months after the lung resection, showed two tumoral masses in the pancreas at the junction of the head and body. Whole-body positron emission tomography (PET) performed in September 2011 (Figure 2) showed heterogeneous enhancement at the level of the pancreatic head with metabolic activity, indicating malignant potential of the lesions, and no evidence of extrapancreatic metastatic lesions.

Figure 2
figure 2

Positron emission tomography/computed tomography revealed a mass in the pancreatic head with metabolic activity.

The oncological context and the multiplicity of the pancreatic lesions following the metastatic pulmonary disseminations oriented the diagnosis towards pancreatic metastases rather than a primary pancreatic tumor. In terms of the biohumoral markers, the carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) levels were as follows: 2 ng/ml; CA 19-9, 14 U/ml; however, an above upper limit level of chromogranin A could have allowed a differential diagnosis of a primary pancreatic neuroendocrine tumor.

Because of the previous episode of lung metastases, which suggested systemic dissemination, probably with other occult metastatic lesions, the oncological panel decided on systemic chemotherapy. In September 2011, the patient was switched to a combination of gemcitabine (1,800 mg/m2) plus dacarbazine (500 mg/m2). PET/CT performed in December 2013 showed a slight increase in the size of the pancreatic lesions and no signs of extrapancreatic recurrence. Because acquired chemoresistance was suspected and because the disease was apparently limited to the pancreas, a decision was made to perform a pancreatic resection. In April 2014, a pylorus-preserving pancreaticoduodenectomy was performed (Figure 3). Microscopically, the surgically resected pancreatic specimen showed features similar to those of the uterine LMS. The immunohistochemical studies showed that the neoplastic cells were positive for SMA and desmin and negative for chromogranin and synaptophysin.

Figure 3
figure 3

Surgical specimen from the pancreaticoduodenectomy.

The patient’s postoperative course was uneventful, and she was discharged on the 12th postoperative day. To date, the patient is alive, without any evidence of recurrence.

Discussion

Pancreatic isolated metastases are a rare condition, most frequently originating from primary renal cell carcinomas [8]. The incidence of metastatic pancreatic tumors has been reported to be 3% to 11% [9, 10]. A uterine sarcoma metastasized to the pancreas is an extremely rare condition which ensures that the decision regarding treatment is difficult and nonstandardized. The decision is determined by an attending multidisciplinary oncology team.

Differentiation of a primary pancreatic adenocarcinoma or of neuroendocrine tumors from a metastatic pancreatic tumor is required to perform neoadjuvant therapy. CT and magnetic resonance imaging are used for the evaluation of the pancreatic mass. Highly vascularized tumors are more likely to be metastases than primary tumors, which are hypovascular. The difficulty lies in distinguishing the tumors, on the basis of imaging, between pancreatic metastatic tumors and pancreatic neuroendocrine tumors, which are hypervascular as well [11]. Percutaneous fine-needle aspiration (FNA) is helpful in the preoperative differential diagnosis between a primary and metastatic pancreatic tumor. However, the published data have shown a difference between the immunohistochemical findings on the endoscopic ultrasound-guided FNA (EUS-FNA) and the final immunohistochemistry results from the resected specimen.

The survival benefit of the resection of pancreatic metastases has been demonstrated. Reddy and Wolfgang [12], in a systemic review of the literature, evaluated 243 patients who had undergone radical pancreatic resection for metastatic disease and concluded that the effectiveness of pancreatic resection for a metastatic tumor is dependent on the tumor biology of the primary cancer. In other case reports [3, 5, 6, 10, 1317], authors have described good long-term survival following an aggressive surgical approach, indicating a possible benefit of surgery in the metastatic setting for selected cases (Tables 1 and 2).

Table 1 First recurrence of pancreatic tumor
Table 2 Second recurrence of pancreatic tumor

In our patient, the long interval between the detection of the pancreatic mass and its resection (33 months), during which time the patient was managed by subsequent cycles of chemotherapy, provided the reason for the oncologist’s and surgeon’s reluctance to resort to surgery, questioning its benefit in a secondary metastatic setting. A wait-and-see attitude regarding chemotherapy was preferred, and the decision to perform surgery was taken as a result of suspected chemoresistance after a long interval of stable disease.

Conclusions

Surgery can be considered in the pancreas as a unique metastatic site or even in cases with resectable oligometastases. We hypothesize that a long disease-free interval following resection of a primary tumor might be an indicator of a more indolent tumor biology or chemoresponsiveness, and thus we question the possibility of the surgical benefit for these select cases.

Consent

Written informed consent was obtained from the patient for publication of this Case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CT:

Computed tomography

FNA:

Fine-needle aspiration

LMS:

Leiomyosarcoma

PET:

Positron emission tomography.

References

  1. 1.

    Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein M, Dunne ME, Rudolph J: Uterine sarcomas: natural history, treatment and prognosis. Cancer. 1978, 42: 1152-1160. 10.1002/1097-0142(197809)42:3<1152::AID-CNCR2820420319>3.0.CO;2-L.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Salazar OM, Dunne ME: The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phys. 1980, 6: 899-902. 10.1016/0360-3016(80)90334-X.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Ozturk S, Unver M, Ozturk BK, Bozbıyık O, Erol V, Kebabcı E, Olmez M, Zalluhoglu N, Bayol U: Isolated metastasis of uterine leiomyosarcoma to the pancreas: report of a case and review of the literature. Int J Surg Case Rep. 2014, 5: 350-353. 10.1016/j.ijscr.2014.04.016.

    PubMed Central  Article  PubMed  Google Scholar 

  4. 4.

    Rose PG, Piver MS, Tsukada Y, Lau T: Patterns of metastasis in uterine sarcoma: an autopsy study. Cancer. 1989, 63: 935-938. 10.1002/1097-0142(19890301)63:5<935::AID-CNCR2820630525>3.0.CO;2-9.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Iwamoto I, Fujino T, Higashi Y, Tsuji T, Nakamura N, Komokata T, Douchi T: Metastasis of uterine leiomyosarcoma to the pancreas. J Obstet Gynaecol Res. 2005, 31: 531-534. 10.1111/j.1447-0756.2005.00344.x.

    Article  PubMed  Google Scholar 

  6. 6.

    Alonso Gómez J, Arjona Sánchez A, Martínez Cecilia D, Díaz Nieto R, Roldán de la Rúa J, Valverde Martínez A, Lizárraga Febres E, Padillo Ruiz J, Rufián Peña S: Uterine leiomyosarcoma metastasis to the pancreas: report of a case and review of the literature. J Gastrointest Cancer. 2012, 43: 361-363. 10.1007/s12029-010-9172-x.

    Article  PubMed  Google Scholar 

  7. 7.

    Ogura T, Masuda D, Kurisu Y, Miyamoto Y, Hayashi M, Imoto A, Takii M, Takeuchi T, Inoue T, Tokioka S, Uchiyama K, Umegaki E, Higuchi K: Multiple metastatic leiomyosarcoma of the pancreas: a first case report and review of the literature. Intern Med. 2013, 52: 561-566. 10.2169/internalmedicine.52.8594.

    Article  PubMed  Google Scholar 

  8. 8.

    Sweeney JT, Crabtree DK, Yassin R, Somogyi L: Metastatic uterine leiomyosarcoma involving the pancreas diagnosed by EUS with fine-needle aspiration. Gastrointest Endosc. 2002, 56: 596-597. 10.1016/S0016-5107(02)70460-4.

    Article  PubMed  Google Scholar 

  9. 9.

    Adsay NV, Andea A, Basturk O, Kilinc N, Nassar H, Cheng JD: Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Arch. 2004, 444: 527-535.

    Article  PubMed  Google Scholar 

  10. 10.

    Falconi M, Crippa S, Sargenti M, Capelli P, Pederzoli P: Pancreatic metastasis from leiomyosarcoma of the broad ligament of the uterus. Lancet Oncol. 2006, 7: 94-95. 10.1016/S1470-2045(05)70543-X.

    Article  PubMed  Google Scholar 

  11. 11.

    Z’graggen K, Fernandez-del Castillo C, Rattner DW, Sigala H, Warshaw AL: Metastases to the pancreas and their surgical extirpation. Arch Surg. 1998, 133: 413-419. 10.1001/archsurg.133.4.413.

    Article  PubMed  Google Scholar 

  12. 12.

    Reddy S, Wolfgang CL: The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009, 10: 287-293. 10.1016/S1470-2045(09)70065-8.

    Article  PubMed  Google Scholar 

  13. 13.

    Clemente G, Giordano M, De Rose AM, Nuzzo G: Image of the month: metastasis from leiomyosarcoma in the head of the pancreas. Arch Surg. 2010, 145: 793-794. 10.1001/archsurg.2010.143-a.

    Article  PubMed  Google Scholar 

  14. 14.

    Hernández S, Martín-Fernández J, Lasa I, Busteros I, García-Moreno F: Pancreaticoduodenectomy for metastasis of uterine leiomyosarcoma to the pancreas. Clin Transl Oncol. 2010, 12: 643-645. 10.1007/s12094-010-0571-z.

    Article  PubMed  Google Scholar 

  15. 15.

    Skagias L, Ioulia E, Politi E: Isolated pancreatic metastasis of uterine leiomyosarcoma diagnosed by fine needle aspiration biopsy. Acta Cytol. 2010, 54: 239-240. 10.1159/000325021.

    Article  PubMed  Google Scholar 

  16. 16.

    Kao YH, Saad U, Tan AE, Magsombol BM, Padhy AK: Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas. Acta Radiol. 2011, 52: 463-466. 10.1258/ar.2011.100509.

    Article  PubMed  Google Scholar 

  17. 17.

    Chatzipantelis P, Karvouni E, Fragoulidis GP, Voros D, Pafiti A: Clinicopathologic features of two rare cases of mesenchymal metastatic tumors in the pancreas: review of the literature. Pancreas. 2006, 33: 301-303. 10.1097/01.mpa.0000234075.53630.2f.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This manuscript has been supported by National research grant PNII-PT-PCCA 90/2012 and by the Romanian - EEA Research Programme EEA-JRP-RO-NO-2013-1-0363.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Irinel Popescu.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

IP performed the operation, SOD performed the literature search, had responsibility for patient care, SO D and NB wrote the paper, MAE collected radiological materials, obtained patient consent, IP, SOD and NB proofread the paper. All authors read and approved the final manuscript.

Simona Olimpia Dima, Nicolae Bacalbasa contributed equally to this work.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Authors’ original file for figure 3

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dima, S.O., Bacalbasa, N., Eftimie, M.A. et al. Pancreatic metastases originating from uterine leiomyosarcoma: a case report. World J Surg Onc 12, 405 (2014). https://doi.org/10.1186/1477-7819-12-405

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1477-7819-12-405

Keywords

  • Pancreatic metastases
  • Resectable oligometastases
  • Uterine leiomyosarcoma